Pharmacological correction of misfolding of ABC proteins  by Rudashevskaya, Elena L. et al.
TECHNOLOGIES
DRUG DISCOVERY
TODAY
Pharmacological correction of
misfolding of ABC proteins§
Elena L. Rudashevskaya1, Thomas Stockner2, Michael Trauner3,
Michael Freissmuth2, Peter Chiba1,*
1Institute of Medical Chemistry, Medical University of Vienna, Waehringerstrasse 10, Vienna, Austria
2Institute of Pharmacology, Medical University of Vienna, Waehringerstrasse 13, Vienna, Austria
3Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, Austria
Drug Discovery Today: Technologies Vol. 12, 2014
Editors-in-Chief
Kelvin Lam – Simplex Pharma Advisors, Inc., Boston, MA, USA
Henk Timmerman – Vrije Universiteit, The Netherlands
Transporter assaysThe endoplasmic reticulum (ER) quality control sys-
tem distinguishes between correctly and incorrectly
folded proteins to prevent processing of aberrantly
folded conformations along the secretory pathway.
Non-synonymous mutations can lead to misfolding of
ABC proteins and associated disease phenotypes. Spe-
cific phenotypes may at least partially be corrected by
small molecules, so-called pharmacological chaper-
ones. Screening for folding correctors is expected to
open an avenue for treatment of diseases such as cystic
fibrosis and intrahepatic cholestasis.
Introduction
About one-third of the eukaryotic genome encodes for pro-
teins that are processed along the secretory pathway. The
endoplasmic reticulum quality control system ascertains cor-
rect folding as a prerequisite for coat protein complex II
(COPII) dependent ER-export. Equating proper folding with
correct function allows the ER to check thousands of proteins
for proper assembly with a limited set of auxiliary proteins.
Nevertheless, function of ABC proteins is often only modestly§ This is an open-access article distributed under the terms of the Creative Commons
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reduced in misfolded mutants relative to wild type. Even a
minor fraction of wild type activity often suffices to alleviate
disease related symptoms. The pharmacological chaperone
concept proposes folding correction by small molecules to
trigger anterograde trafficking of proteins to their final
cellular destinations. It also relies on the assumption that
the residual function of the proteins suffices to suppress a
disease phenotype. Here, development in cell-based high-
throughput screening techniques is discussed with respect
to correction of ABC protein folding.
Aberrant folding of ABC proteins and human disease
ER-associated degradation (ERAD) of mutant ABC proteins
results in several potentially lethal or debilitating human
diseases. The available evidence indicates misfolding and
premature degradation caused by missense mutations as a
significant cause of membrane protein deficiencies [1]. Dis-
ease causing mutations in several human ABC proteins,
including among others ABCA1 (Tangier disease), ABCB4
(progressive familial intrahepatic cholestasis type 3), ABCB11
(progressive familial intrahepatic cholestasis type 2), ABCC2
(Dubin-Johnson syndrome), ABCC7 (cystic fibrosis), ABCC8
(hyperinsulinemic hypoglycemia of infancy) and ABCG2
(gout), have been linked to aberrant folding, retrotransloca-
tion of proteins into the cytoplasm and subsequent protea-
somal degradation [1].oi.org/10.1016/j.ddtec.2014.03.009 e87
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Theminimum functional formofABC-exporterscomprises four
domains. Two membrane spanning (transmembrane) domains
confer solute (substrate) specificity, while two nucleotide bind-
ing domains, which bind and hydrolyze ATP in two composite
nucleotide binding sites, provide the energy for the movement
of solutes across membranes. An analogous architecture can be
observed in all presently available ABC exporter crystal struc-
tures. The folding process may be considered a stepwise process,
in which (sub)domain folding precedes correct positioning of
domains or subdomains relative to each other. Impairment of
either of these processes can result in the absence of functional
protein [2]. A crucial point in adopting the native conformation
is a partial domain-swap in the architecture of ABC exporters,
which requires engagement of the second intracellular loop
(ICL) of each transmembrane domain (TMD) (ICL 2 and 20 in
half transporters and ICLs 2 and 4 in full transporters) into a
socket of the contralateral nucleotide binding domain (NBD)
via so-called coupling helices. Thereby coupling helices insert
between the core- and the a-helical subdomains of each NBD.
Charge interactions in conserved positions of the NBDs and
ICLs stabilize this conformation. Figure 1a illustrates the archi-
tecture in a schematic way. Note that only the front side of theC
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Figure 1. Schematic representation of ABC protein architecture, misfolding and co
two halves of a full transporter are shown in light and dark blue. TMDs and ICLs are s
the a-helical subdomains of NBD, respectively. Parts of the TMD-NBD interface a
subdomain of the respective contralateral NBD. (b) Misfolded protein – incorrect f
NBD. (d) Position of one substrate binding site in the TMD of correctly folded p
pharmacochaperone (yellow circle) bound to substrate binding site (orange). (f) Cor
direct binding of corrector molecule (green circle) to exosite of NBD (blue circle). A
the scaffold of a correctly positioned ICL 2/4 to the respective NBD. NBD, nucleo
e88 www.drugdiscoverytoday.comprotein is visible, but the process has to proceed in an identical
manner on the back side also. In ABCB1, a multispecific drug
efflux transporter, this process of contralateral engagement
of ICLs 2/4 contributes to the formation of two pseudosym-
metric solute binding sites, which are formed by contribu-
tions from residues located in the membrane spanning
portion of helix-pairs 5/8 and 2/11 respectively [3] (one
of these is shown in Fig. 1d). Successful folding has been
shown to require both, correct folding of the NBD socket
and ICLs, and proper formation of the NBD-TMD interfaces.
If either of these processes – domain interface formation
(Fig. 1b) or domain folding (Fig. 1c) – fails, the protein
misfolds. Active site compounds can correct folding defi-
cient mutants of ABCB1 (unpublished) (Fig. 1e). Despite the
presence of a transmission-interface  destabilizing missense
mutation, the protein adopts a functionally active confor-
mation. For the rescue of misfolded (sub)domains a correc-
tor might be required to bind to the misfolded domain
directly (Fig. 1f). Circumstantial evidence for binding to
an exosite (non-active site) has been presented in a recent
publication on ABCC7, in which direct binding of the
corrector compound VX-809 to the misfolded NBD of the
delta F508 mutant has been postulated by docking [4].IC
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rrection with pharmacochaperones. (a) Architecture of folded protein. The
hown as rectangles, NDBs as circles. C and a refer to the core (F1 type) and
re formed by engagement of ICL2 (ICL4) into the socket between C and a
ormation of TMD-NBD interface. (c) Misfolded protein – misfolding of one
rotein (orange circle). (e) Correction of misfolded domain interface by
rection of misfolded protein with one disrupted NBD. Rescue might require
lternatively, an active site compound might also correct folding, by providing
tide binding domain; TMD, transmembrane domain; ICL, intracellular loop.
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Figure 2. (a) Pathways for folded and misfolded ABC proteins. (b)
Schematic representation of the dynamics (change in time) in protein
amount (at correct cellular localization, red curve) and
pharmacochaperone plasma level (blue). Activity can be expected for
non-overlapping areas (shaded in gray).Circumvention of potential functional inhibition by corrector
molecules
Figure 2a shows a misfolded ABC protein destined for pro-
teasomal degradation. The presence of a corrector allows its
trafficking to the plasma membrane. At the same time, cor-
rectors can potentially inhibit function of the protein, for
example by occupying the active sites. The half-life of an ABC
transporter is determined by ER-export rates on one hand and
internalization/recycling/lysosomal degradation on theO
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Figure 3. Chemical structures of two corrector molecules which entered cliother hand. An intermittent treatment regimen with correc-
tors would, however, allow a potential inhibitory action of
compounds to be released and the protein to become active, if
compound elimination were shorter than the resident time of
the transporter at its correct cellular membrane localization
(Fig. 2b). Activity of the protein would be expected for non-
overlapping portions of the blue and red curves. These gray-
shaded areas refer to time intervals, during which drug levels
decrease, but protein is retained at its site of action (Fig. 2b).
Is there a proof of principle for folding correction by pharmacological
chaperones?
A proof of principle for use of small molecule correctors has
been established in vivo by recent approval of a corrector for
the treatment of phenylketonuria (sapropterin (tetrahydro-
biopterin) is the cofactor for the enzyme phenylalanine-
hydroxylase) [5]. A small molecule trafficking rescue
approach is also actively pursued for cystic fibrosis, the most
frequent lethal inherited disease, in which an airway epithe-
lial chloride channel, CFTR (cystic fibrosis transmembrane
conductance regulator; ABCC7) is impaired. Screening pro-
grams have been initiated in academic/industrial joint ven-
tures [6,7]. Two corrector molecules have entered clinical
studies. For one of the compounds, VX-809 (Fig. 3a) a phase
II clinical study has been concluded in 2012. A phase III study
will begin in 2013, in which this corrector is combined with
the recently approved functional potentiator compound VX-
770. A second compound, VX-661 (Fig. 3b) is presently
evaluated in a clinical phase II study (CF foundation:
http://www.cff.org/research/ClinicalResearch/). Successful
mutation-specific chaperone therapy with 4-phenylbutyrate
has recently been reported as proof of principle in a child with
progressive familial intrahepatic cholestasis type 2 [8].O
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nical studies: (a) VX-809 and (b) VX-661.
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Figure 4. Synopsis of ABC protein assays used for screening. (a)
Assays for detection of protein localization. From left to right:
fluorescent tags: GFP and mCherry in combination with Flag-tag;
fluorescent antibodies: antibodies against a genuine extracellular
epitope of an ABC protein, or an extracellular HA-tag; fluorogen-
activating protein (FAP) (introduced as an extracellular tag of an ABC
protein). (b) Functional assays. From left to right: detection of
chloride transport of ABCC7 based on the substrate-sensitive
fluorescence of coexpressed YFP protein and a voltage-sensitive
fluorescent dye; direct detection of fluorescent substrate of the ABC
protein (ABCA1 and ABCB1 are given as examples); and simultaneous
observation of substrate and GFP-labeled ABC protein. The detection
techniques (confocal microscopy, microplate reader, and flow
cytometry) are indicated for each approach according to information
in the literature as cited in the text. Colors refer to the respective
cellular localization of the fluorescent dye (intracellular, or cell
membrane).Which ABC protein related diseases and which mutations should be
used for screening of pharmacochaperones?
A search for correctors of ABC transporter misfolding is
primarily indicated for diseases devoid of treatment alterna-
tives. These include the most frequent lethal inherited disease
cystic fibrosis, pseudoxanthoma elasticum, gout, intrahepa-
tic cholestasis and liver disease. The most recent addition to
successful folding-correction is congenital hyperinsulinism.
In vitro data suggest that for a subset of sulfonylurea receptor 1
(SUR1) mutations potassium channel activity can be cor-
rected by carbamazepine [9].
Screens are usually conducted with mutations that are
frequent in populations. The DF508 mutation in ABCC7 is
present in at least one allele in 90% of cystic fibrosis patients
[10] while the E297G and D482G mutations in ABCB11 are
found (individually or in combination) in close to 60% of
European families affected by progressive familial intrahepa-
tic cholestasis type II [11]. These frequent mutations repre-
sent logical starting points for screening efforts.
Screening techniques used in the identification of folding correctors
To ascertain correct cellular localization, screening for phar-
macological chaperones of membrane proteins requires cell-
based assays. Trafficking correction is only beneficial in cases,
in which protein function is at least partially retained. Two
different types of assays have been described: (i) those that
yield information on protein localization, or (ii) those that
probe protein function as a reflection of both, correct cellular
localization and residual functional activity. The latter repre-
sents the preferable option for mutations in which stronger
functional impairment is expected. Also, combinations of
correctors and potentiators (compounds that activate ABC-
proteins) can be assessed.
Most of the available literature on ABC proteins is on the
cystic fibrosis transmembrane conductance regulator
(ABCC7), which was and is the most extensively studied
ABC protein both in academic, industrial and joint aca-
demic/industrial ventures. Several reviews on available assay
technologies have appeared in print [6,12]. ABCG2 has
recently been identified as a major uric acid efflux transporter
in renal tubular epithelial cells [13]. Hyperuricemia and gout
are linked to a frequent folding deficient single nucleotide
polymorphism (Q141K), which leads to a folding defect in
the encoded protein and is found at particularly high fre-
quency in the Japanese population. Functional assays of
ABCG2 have been reviewed [14]. Techniques described there
include vesicular ATPase and transport assays, which can be
used for functional assays of ABC proteins, but not all of them
have the potential to be adapted to a high-throughput setting
for screening of folding correction. Detection of the fully
glycosylated mature form of ABC proteins in polyacrylamide
gels by Western blotting [9] unfortunately is not easily
adapted to the setting of high-throughput screening,e90 www.drugdiscoverytoday.comalthough it represents a gold standard for further character-
ization of hits.
High- or ultra-high-throughput screening technologies
afford the identification of hits from compound libraries
within the scope of days. In this review we intend to sum-
marize screening approaches for correctors of folding defi-
cient ABC proteins with a focus on high-throughput
technologies. Other functional assays that require a more
extensive pre-screening effort, such as purification of vesicles
or protein, are not subject of the current review.
Assays for detection of protein localization
Misfolding affects protein processing in the endoplasmic
reticulum and directs proteins to ERAD. Thus retention of
a plasma membrane protein in the ER is indicative of a
Vol. 12, 2014 Drug Discovery Today: Technologies | Transporter assaysprotein folding defect. The following three approaches,
which are depicted in a schematic way in Fig. 4a are com-
monly used.
Fluorescent tags
Fluorescence microscopy with confocal optics is broadly used
for localization studies of membrane proteins. Almost 20
years ago GFP-tags have been introduced to trace cellular
localization and routing of proteins of interest to different
cellular compartments. GFP-tagging has proven useful in
confocal microscopy studies of several ABC proteins includ-
ing ABCG2 [15]. Obviously, modest variations in the nature
of the fluorescent proteins do not have any impact, for
example, a YFP tag was used for ABCA3, a transporter
involved in surfactant production in alveolar type II cells
[16]. Early on, the potential for scale-up has been realized and
high throughput approaches have been developed that use
fully automated fluorescent microscopy imaging [17]. So-
called high content microscopy-based assays, which assess
a cell phenotype by image analysis, were applied to study
trafficking of the CFTR protein [7]. In these studies authors
used mCherry and a FLAG-epitope tag on the same protein.
This allowed quantification of cell surface expression with an
anti FLAG antibody and comparison with the total amount of
CFRT in cells as estimated by the mCherry tag (Fig. 4a).
Though a GFP-tag proved useful for a range of ABC pro-
teins, it failed in case of ABCA4, because it caused misloca-
lization of the protein. Therefore, visualization had to rely on
an anti ABCA4 antibody and a fluorescent secondary anti-
body [18].
Antibodies
The on-cell western (life cell western) assay represents a
robust approach, which uses fluorescent antibodies that
recognize epitopes exposed to the cell exterior, in combina-
tion with multi-well screening. The fluorescence of proteins
at the cell surface can be verified without a requirement for
microscopic imaging. However, the technique relies on the
availability of antibodies directed against extracellular loops
of ABC proteins.
The use of anti ABCC7 antibodies has been reviewed
[12,19]. Similar studies have been conducted with ABCA4
[18]. The use of specific cell surface antibodies for ABCB1 and
ABCG2 has also been reviewed [14].
In many instances antibodies against extracellular epitopes
are not available. This limitation can be overcome by inser-
tion of the small hemaglutinin (HA) epitope into tolerant
regions of the protein sequence. This strategy has proven
feasible in the analysis of CFTR with on-cell western assays to
determine CFTR turnover with a fluorescent secondary anti-
body [20]. Alternatively, the HA-tag in CFTR can be visualized
with an HRP-conjugated primary antibody [12]. The HA-tag
in combination with a secondary fluorescent antibody hasalso successfully been applied for ABC proteins from other
ABC subfamilies including ABCA3 [16]. In the latter study,
the cellular localization of the transporter was visualized by
confocal microscopy.
Fluorogen-activating proteins
An interesting approach is the use of fluorogen-activating
proteins (FAPs), which has recently been applied to study the
efficiency of compounds in rescuing trafficking of CFTR
mutant DF508 [21]. FAPs are tags that are fused to proteins
so that they are exposed to the cell exterior. Upon binding,
these tags increase fluorescence of a fluorogen that is present
in solution. The authors used confocal microscopy to visua-
lize the presence of protein at the plasma membrane and
suggest that the approach can be adapted to multi-well plate
screening.
Approaches using tags and fluorescence detection can in
principle be applied to all ABC proteins, provided that the
tags themselves do not interfere with trafficking of the tar-
geted proteins.
Functional assays
Even if folding deficiencies are rescued by pharmacological
agents, and protein localization is corrected, the transport
activity of the protein may still be compromised to variable
extent. Functional assays offer the advantage that they verify
both the ability of a small molecule corrector to promote ER-
export of the protein and functional activity at the correct
cellular destination.
Functional assays are based on direct detection of fluores-
cent substrates, or fluorescent sensors reporting translocation
of substrates of ABC proteins (Fig. 4b).
Halide-sensitive fluorescent probe
This approach utilizes a halide sensitive YFP variant to esti-
mate chloride conductance of CFTR. As this approach is
limited to the detection of halides, it can only be used to
study CFTR. In the presence of chloride ions the probe
fluoresces. Upon changing chloride to iodide containing
medium, iodide replaces chloride leading to quenching of
YFP [22–24]. High throughput screening of small molecules
for CFTR DF508 trafficking correction has been performed by
coexpression of CFTR and halide-sensitive YFP.
Detection of a membrane potential change
Similar to the above described method, this technique is also
only applicable to CFTR. Cl efflux leads to a change in
membrane potential, which can be detected by fluorescent
voltage sensitive probes [25].
Fluorescent transport substrates
If available, ABC transporters can be studied by using fluor-
escent substrates. One possible way of detecting fluorescentwww.drugdiscoverytoday.com e91
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Table 1. Examples of fluorescent substrates and techniques used to investigate transport activity of ABC proteins
ABC protein Disease Substrate (natural) Substrate in experiment Technology
ABCA1 (CERP) TGD Cholesterol [28] Pennsylvania Green/N-alkyl-3b-
cholesterylamine-derived
probe (F-Ch) [29]
Microplate reader, HTS [29]
ABCB1 (Pgp1) MDR Large hydrophobic molecules,
anticancer drugs, HIV protease
inhibitor [26]; reviewed in [27]
Rhodamine 123 [30] Confocal microscopy [30]
Calcein acetoxymethyl ester
(CaAM) [31], JC1 [31,32]
Flow cytometry, HTS [31,32]
eFluxx-ID Green, eFluxx-ID
Gold [33,34]
Flow cytometry [33,34]
Reviewed in [26]
ABCB11 (BSEP) PFIC-2 Bile salts 3a- and 3b-NBD-UDCA [35] Microplate reader [35]
ABCC2 (MRP2) DJS;
MDR
Organic ions [28];
Reviewed in [36]
Lopinavir (LPV), calcein,
carboxyfluorescein diacetate [37]
Glutathione-Methylfluorescein [38],
Glutathione-Monochlorobimane [38,39]
Microplate reader [38,39]
ABCC6 (MRP6) PXE; MDR Drugs, organic ions;
Reviewed in [40]
Glutathione conjugate of N-ethylmaleimide
(NEM-GS) [41], leukotriene C4 (LTC4)
[41,42]; reviewed in [40]
Vesicular assays,
radioactivity [41,42]
ABCG2 (BCRP) Gout; MDR Anionic compounds and hydrophobic
drugs [26]; reviewed in [27]
Mitoxantrone (MX) [43] Confocal microscopy [43]
JC1 [31] Flow cytometry, HTS [31]
eFluxx-ID Green, eFluxx-ID Gold [34] Flow cytometry [34]
Reviewed in [26]
Abbreviations: TGD, Tangier disease; MDR, multi drug resistance; PFIC-2, progressive familial intrahepatic cholestasis type 2; DJS, Dubin-Johnson syndrome; PXE, pseudo-xanthoma
elasticum; HTS, high throughput screen; JC1, J-aggregate-forming lipophilic cation 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide; NBD, 4-nitrobenzo-2-oxa-1,3-
diazol; UDCA, ursodeoxycholic acid.
Commonly used alternative designations of ABC proteins are given in parenthesis next to the systematic classification identifier.substrates is by means of flow cytometry. This technique is
widely used for the evaluation of the activity of surface
expressed ABC transporters and detects transport rates as a
surrogate parameter for protein localized at the cell mem-
brane. Table 1 lists examples of substrates of ABC proteins
that can be used for functional tracking of folding deficient
mutations. The substrates for multidrug transporting pro-
teins have been reviewed elsewhere [26,27].
Flow cytometry has previously been employed for HTS
assays not only of multidrug resistance proteins – ABCB1
[31,32], ABCG2, and ABCC1 [31], but also of ABCB6, which
recognizes protoporphyrin as a transport substrate [44].
Alternatively, microplate-based HTS platforms have been
used to detect the transport of fluorescent substrates by
multidrug transporters [45], and also for monitoring flux of
a fluorescently labeled cholesterol analog by ABCA1 [29].
Yet another method used to estimate the transport of
fluorescent substrates is confocal microscopy. This approach
allows for simultaneous recording of cellular Hoechst 33342
or mitoxantrone accumulation and cellular localization of
GFP-ABCG2 [15,43]. It was also employed to document trans-
port of nitrobenzoxadiazole-labeled lipids and the localiza-
tion of ABCA3-DsRed [16].e92 www.drugdiscoverytoday.comConclusions
A vast number of causative mutations have been described for
the at least 25 different disease entities associated with ABC-
transporter malfunction. However, only recently the impor-
tance of protein misfolding due to missense mutation has
been appreciated as a significant mechanism in the etiology
of ABC transporter-linked diseases beyond the well estab-
lished example of the inherited disease of cystic fibrosis.
The mutations, which cause folding deficiency of different
ABC transporters, cluster at hot spots indicative of structural
conservation (unpublished data). Small molecule correctors
are able to counteract the destabilizing effect of mutations by
achieving sufficient thermodynamic stabilization of other-
wise misfolded proteins. This allows them to pass the quality
control checkpoint of the ER and commence their journey to
their final cellular destinations. The pharmacochaperone
concept posits residual functional activity to be associated
with proteins, even when having lower thermodynamic sta-
bility.
Extensive efforts have been directed toward identifying
corrector molecules for the treatment of the most frequent
lethal inherited disease, cystic fibrosis. Nonetheless misfold-
ing has increasingly been appreciated as a more common
Vol. 12, 2014 Drug Discovery Today: Technologies | Transporter assayscause of ABC-transporter associated diseases including,
among others, severe liver diseases.
With respect to screening platforms, whole cell based
assays are required for the assessment of corrector action.
Available techniques can coarsely be classified into either
localization assays or functional assays. The latter have the
potential advantage that they not only assess correct pro-
tein localization, but also confirm that a functional protein
has been delivered to the correct cellular destinations.
Hybrid assays that allow simultaneous detection of func-
tion and localization have also been described. Microscopy,
flow cytometry and microplate assays represent alterna-
tives, in which each has its individual merits. Speed, robust-
ness and amount of information provided by the respective
assay system have to be weighed against each other. It may
be expected that the refined and rapid assay technologies
for CFTR corrector action in high and ultra high throughput
screening platforms will be matched by the scale up of
technologies for other ABC proteins. Some of these pre-
sently rely on more tedious systems, including indirect
methods.
It should be kept in mind that mutations and correctors
probably form dedicated pairs and that only a subset of
known mutations will be amenable to corrector action. It
will also be necessary to clarify if an activity ceiling, as
described for cystic fibrosis correctors, also exists for other
ABC-transporter mutants.
Further development and refinement of assay systems will
lay a foundation for the identification and clinical develop-
ment of correctors, primarily for those severe diseases that are
caused by frequent natural variants of ABC-transporters.
Expectations are high so that this development will make
those diseases, for which treatment options presently do not
exist, amenable to therapeutic intervention in the near future.
Conflict of interests
The authors declare that they have no conflict of interest.
Acknowledgement
This work has been funded by the Austrian Science Fund
SFB35 project part 3509.
References
1. Nakagawa H, Toyoda Y, Wakabayashi-Nakao K, Tamaki H, Osumi M,
Ishikawa T. Ubiquitin-mediated proteasomal degradation of ABC
transporters: a new aspect of genetic polymorphisms and clinical impacts. J
Pharm Sci 2011;100:3602–19.
2. Rabeh WM, Bossard F, Xu H, Okiyoneda T, Bagdany M, Mulvihill CM, et al.
Correction of both NBD1 energetics and domain interface is required to
restore DeltaF508 CFTR folding and function. Cell 2012;148:150–63.
Experimental evidence that both domain folding and domain interface
formation is required for trafficking correction.
3. Parveen Z, Stockner T, Bentele C, Pferschy S, Kraupp M, Freissmuth M, et al.
Molecular dissection of dual pseudosymmetric solute translocation
pathways in human P-glycoprotein. Mol Pharmacol 2011;79:443–52.4. He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, et al.
Correctors of DeltaF508 CFTR restore global conformational maturation
without thermally stabilizing the mutant protein. FASEB J 2013;27:536–645.
5. Harding CO. New era in treatment for phenylketonuria: pharmacologic
therapy with sapropterin dihydrochloride. Biologics 2010;4:231–6.
6. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the
DeltaF508 conformational defect. Trends Mol Med 2012;18:81–91.
7. Almaca J, Dahimene S, Appel N, Conrad C, Kunzelmann K, Pepperkok R,
et al. Functional genomics assays to study CFTR traffic and ENaC function.
Methods Mol Biol 2011;742:249–64. Authors use high content microscopy
based assays to monitor trafficking of CFTR. A double tagging allows extent
of trafficking to be evaluated.
8. Gonzales E, Grosse B, Cassio D, Davit-Spraul A, Fabre M, Jacquemin E, et al.
Successful mutation-specific chaperone therapy with 4-phenylbutyrate in
a child with progressive familial intrahepatic cholestasis type 2. J Hepatol
2012;57:695–8.
9. Chen P-Ch, Olson EM, Zhou Q, Kryukova Y, Sampson HM, Thomas DY,
et al. Carbamazepine as a novel small molecule corrector of trafficking-
impaired ATP-sensitive potassium channels identified in congenital
hyperinsulinism. J Biol Chem 2013;288:20942–54.
10. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem
2008;77:701–26.
11. Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerova D, Rayner A,
Dutton L, et al. Severe bile salt export pump deficiency: 82 different
ABCB11 mutations in 109 families. Gastroenterology 2008;134:1203–14.
12. Peters KW, Okiyoneda T, Balch WE, Braakman I, Brodsky JL, Guggino WB,
et al. CFTR Folding Consortium: methods available for studies of CFTR
folding and correction. Methods Mol Biol 2011;742:335–53.
13. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen
M. Identification of a urate transporter, ABCG2, with a common
functional polymorphism causing gout. Proc Natl Acad Sci U S A
2009;106:10338–42.
14. Hegedus C, Szakacs G, Homolya L, Orban TI, Telbisz A, Jani M, et al. Ins and
outs of the ABCG2 multidrug transporter: an update on in vitro functional
assays. Adv Drug Deliv Rev 2009;61:47–56.
15. Homolya L, Orban TI, Csanady L, Sarkadi B. Mitoxantrone is expelled by
the ABCG2 multidrug transporter directly from the plasma membrane.
Biochim Biophys Acta 2011;1808:154–63.
16. Weichert N, Kaltenborn E, Hector A, Woischnik M, Schams A, Holzinger A,
et al. Some ABCA3 mutations elevate ER stress and initiate apoptosis of
lung epithelial cells. Respir Res 2011;12:4.
17. Conrad C, Wunsche A, Tan TH, Bulkescher J, Sieckmann F, Verissimo F,
et al. Micropilot: automation of fluorescence microscopy-based imaging
for systems biology. Nat Methods 2011;8:246–9.
18. Wiszniewski W, Zaremba CM, Yatsenko AN, Jamrich M, Wensel TG, Lewis
RA, et al. ABCA4 mutations causing mislocalization are found frequently in
patients with severe retinal dystrophies. Hum Mol Genet 2005;14:2769–78.
19. Mendes F, Farinha CM, Roxo-Rosa M, Fanen P, Edelman A, Dormer R, et al.
Antibodies for CFTR studies. J Cyst Fibros 2004;3:69–72.
20. Cholon DM, O’Neal WK, Randell SH, Riordan JR, Gentzsch M. Modulation
of endocytic trafficking and apical stability of CFTR in primary human
airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol
2010;298:L304–14.
21. Holleran JP, Glover ML, Peters KW, Bertrand CA, Watkins SC, Jarvik JW,
et al. Pharmacological rescue of the mutant cystic fibrosis transmembrane
conductance regulator (CFTR) detected by use of a novel fluorescence
platform. Mol Med 2012;18:685–96.
22. Sondo E, Tomati V, Caci E, Esposito AI, Pfeffer U, Pedemonte N, et al.
Rescue of the mutant CFTR chloride channel by pharmacological
correctors and low temperature analyzed by gene expression profiling. Am
J Physiol Cell Physiol 2011;301:C872–85.
23. Phuan PW, Yang B, Knapp JM, Wood AB, Lukacs GL, Kurth MJ, et al.
Cyanoquinolines with independent corrector and potentiator activities
restore DeltaPhe508-cystic fibrosis transmembrane conductance regulator
chloride channel function in cystic fibrosis. Mol Pharmacol 2011;80:683–
93. Halide-sensitive YFP coexpressed with CFTR functions as a sensor for
chloride conductivity of mutant ABCC7 in a high throughput library
screen.www.drugdiscoverytoday.com e93
Drug Discovery Today: Technologies | Transporter assays Vol. 12, 201424. Lin S, Sui J, Cotard S, Fung B, Andersen J, Zhu P, et al. Identification of
synergistic combinations of F508del cystic fibrosis transmembrane
conductance regulator (CFTR) modulators. Assay Drug Dev Technol
2010;8:669–84.
25. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, et al.
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis
airway primary cultures by small molecules. Am J Physiol Lung Cell Mol
Physiol 2006;290:L1117–30.
26. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance
ABCB and ABCG transporters: participation in a chemoimmunity defense
system. Physiol Rev 2006;86:1179–236.
27. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein
(MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug
Metab Pharmacokinet 2012;27:85–105.
28. Fukuda Y, Schuetz JD. ABC transporters and their role in nucleoside and
nucleotide drug resistance. Biochem Pharmacol 2012;83:1073–83.
29. Zhang F. Development of a cell-based, high-throughput screening assay for
cholesterol efflux using a fluorescent mimic of cholesterol. Assay Drug Dev
Technol 2011;9:136.
30. Hammerle SP, Rothen-Rutishauser B, Kramer SD, Gunthert M, Wunderli-
Allenspach H. P-glycoprotein in cell cultures: a combined approach to
study expression, localisation, and functionality in the confocal
microscope. Eur J Pharm Sci 2000;12:69–77.
31. Ivnitski-Steele I, Larson RS, Lovato DM, Khawaja HM, Winter SS, Oprea TI,
et al. High-throughput flow cytometry to detect selective inhibitors of
ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol
2008;6:263–76.
32. Winter SS, Lovato DM, Khawaja HM, Edwards BS, Steele ID, Young SM,
et al. High-throughput screening for daunorubicin-mediated drug
resistance identifies mometasone furoate as a novel ABCB1-reversal agent.
J Biomol Screen 2008;13:185–93.
33. Huber O, Brunner A, Maier P, Kaufmann R, Couraud PO, Cremer C, et al.
Localization microscopy (SPDM) reveals clustered formations of P-
glycoprotein in a human blood-brain barrier model. PLoS ONE
2012;7:e44776.
34. Lebedeva IV, Pande P, Patton WF. Sensitive and specific fluorescent probes
for functional analysis of the three major types of mammalian ABC
transporters. PLoS ONE 2011;6:e22429.
35. Majer F, Salomon JJ, Sharma R, Etzbach SV, Najib MN, Keaveny R, et al.
New fluorescent bile acids: synthesis, chemical characterization, ande94 www.drugdiscoverytoday.comdisastereoselective uptake by Caco-2 cells of 3-deoxy 3-NBD-amino
deoxycholic and ursodeoxycholic acid. Bioorg Med Chem 2012;
20:1767.
36. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug
resistance associated protein 2 (MRP2/ABCC2): its impact on drug
disposition. Adv Drug Deliv Rev 2002;54:1311–31.
37. Elens L, Tyteca D, Panin N, Courtoy P, Lison D, Demoulin JB, et al.
Functional defect caused by the 4544G>A SNP in ABCC2: potential impact
for drug cellular disposition. Pharmacogenet Genomics 2011;21:
884–93.
38. Arlanov R, Porter A, Strand D, Brough R, Karpova D, Kerb R, et al.
Functional characterization of protein variants of the human multidrug
transporter ABCC2 by a novel targeted expression system in fibrosarcoma
cells. Hum Mutat 2012;33:750–62.
39. Uchiumi T, Tanamachi H, Kuchiwaki K, Kajita M, Matsumoto S, Yagi M,
et al. Mutation and functional analysis of ABCC2/multidrug resistance
protein 2 in a Japanese patient with Dubin-Johnson syndrome. Hepatol
Res 2012. http://dx.doi.org/10.1111/j.1872-034X.2012.01103.x.
40. Le Saux O, Martin L, Aherrahrou Z, Leftheriotis G, Varadi A, Brampton CN.
The molecular and physiological roles of ABCC6: more than meets the eye.
Front Genet 2012;3:289.
41. Ilias A, Urban Z, Seidl ThL, Le Saux O, Sinko E, Boyd ChD, et al. Loss of ATP-
dependent transport activity in pseudoxanthoma elasticum-associated
mutants of human ABCC6 (MRP6). J Biol Chem 2002;277:16860–67.
42. Belinsky MG, Chen Z-S, Shchaveleva I, Zeng H, Kruh GD. Characterization
of the drug resistance and transport properties of multidrug resistance
protein 6 (MRP6, ABCC6). Cancer Res 2002;62:6172–7.
43. Orban TI, Seres L, Ozvegy-Laczka C, Elkind NB, Sarkadi B, Homolya L.
Combined localization and real-time functional studies using a GFP-
tagged ABCG2 multidrug transporter. Biochem Biophys Res Commun
2008;367:667–73.
44. Polireddy K, Khan MM, Chavan H, Young S, Ma X, Waller A, et al. A novel
flow cytometric HTS assay reveals functional modulators of ATP binding
cassette transporter ABCB6. PLoS ONE 2012;7:e40005. High throughput
flow cytometry screen of a compound library for pharmacological action
on ABCB6..
45. Held P, Banks P, Lebedeva I, Shen D, Patton W. A fluorescent microplate-
based assay workflow enabling the functional characterization of multi-
drug resistance transporters in living cells. BioTek 2011. Application Note
AN060311_03, Rev.06/03/11.
